| Old Articles: <Older 17511-17520 Newer> |
|---|
 |
The Motley Fool
October 19, 2006
S.J. Caplan |
When Brokers Break the Rules Investors do have some recourse if they feel they've been duped, and that recourse is on sale this month.   |
The Motley Fool
October 19, 2006
Ryan Fuhrmann |
Diageo Toasts 2007 With 2007 targets confirmed, the beverage firm's strong growth should continue. Investors, take note. |
The Motley Fool
October 19, 2006
Brian Lawler |
Where Are The Earnings, USANA? Sales grew, but earnings didn't, compared to last year's third quarter. How much longer will the good times will last for supplement companies? It's anyone's guess, so USANA needs to start growing earnings faster and exhibiting some economies of scale. |
The Motley Fool
October 19, 2006
Rich Smith |
Foolish Forecast: Radyne Rising The tiny telecom equipment maker Radyne is scheduled to report its sixth straight quarter of earnings growth when it releases it third-quarter 2006 earnings report. Investors, take note. |
The Motley Fool
October 19, 2006
Anders Bylund |
AMD's Winning Ways Underappreciated Once again, short-term traders look past juicy long-term opportunities. |
The Motley Fool
October 19, 2006
Anders Bylund |
AMD's Advanced Macro Dinero: Fool by Numbers The underdog chip maker released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 19, 2006
Brian Lawler |
No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note. |
The Motley Fool
October 19, 2006
Brian Lawler |
Marking Time at Serono Things still look good for investors in this soon-to-be-acquired Swiss pharma. |
The Motley Fool
October 19, 2006
Tom Taulli |
CyberSource: Bidding for Growth The developer of electronic payment technologies, has seen its stock price steadily rise from $6.50 to $11.10 this year. The company is benefiting nicely as more transactions move online across the globe. |
The Motley Fool
October 19, 2006
Brian Lawler |
Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note. |
| <Older 17511-17520 Newer> Return to current articles. |
